All In Biotech

Drug Trial Radar · NCT01166542

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 167 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

167

Actual

Start

Jun 2010

Primary completion

Apr 2012

Study completion May 2014

Sponsor

Lead sponsor
Oncolytics BiotechIndustry
Sponsor type
Industry
First posted
Jul 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.

Conditions

  • Carcinoma, Squamous Cell of the Head and Neck

Interventions

  • REOLYSINBiological

    3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle

  • CarboplatinDrug

    5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle

  • PaclitaxelDrug

    175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: every 3 months until death.

Locations

77 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Oncology Associates

    Tucson, Arizona

  • Providence Health and Services

    Burbank, California

  • Wilshire Oncology Medical Group

    Corona, California

  • BMS Physician Practice, A Medical Corporation DBA Medical Oncology Care Associates

    Orange, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Pasco Hernando Oncology Associates, PA

    New Port Richey, Florida

  • Emory University - Winship Cancer Institute

    Altanta, Georgia

  • Alexian Brothers Hospital Network

    Elk Grove Village, Illinois

  • Mary Bird Perkinds Cancer Center - Baton Rouge

    Baton Rouge, Louisiana

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Montefiore Medical Center

    The Bronx, New York

  • Case Comprehensive Cancer Center, University Hospitals Case Medical Center

    Cleveland, Ohio

  • Mercy Cancer Center

    Toledo, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Texas Oncology- Sammons Cancer Center

    Dallas, Texas

  • Cancer Therapy and Research Center at UTHSCSA

    San Antonio, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • Columbia Basin Hematology and Oncology

    Kennewick, Washington

  • ZNA Middelheim

    Antwerp, Belgium

  • University Hospital Antwerp

    Edegem, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Juravinski Cancer Center

    Hamilton, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Hopital Notre-Dame

    Montreal, Quebec, Canada

  • Hopital Saint-André / Service d'Oncologie-Radiothérapie

    Bordeaux, France

  • Centre Antoine Lacassagne / Oncologie Médicale

    Nice, France

  • Institut Curie / Département d'Oncologie Médicale

    Paris, France

  • UKE Hamburg

    Hamburg, Germany

  • Attikon University Hospital

    Athens, Greece

  • Fovarosi Onkormanyzat Uzsoki Utcai Kórház

    Budapest, Hungary

  • Orszagos Onkologiai Intezet

    Budapest, Hungary

  • Pecsi Tudomanyegyetem

    Pécs, Hungary

  • Szegedi Tudományegyetem

    Szegedi, Hungary

  • Markusovszky Korhaz

    Szombathely, Hungary

  • Ufficio Sperimentazioni Cliniche c/o S.C. Oncologia Medica

    Cuneo, Italy

  • Fondazione IRCCS Istituto Nazionale del Tumori

    Milan, Italy

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.